Delving into the Latest Updates on ZKLJ02 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ZKLJ02

Target

F12 x KLKB1

Action

inhibitors

Mechanism

F12 inhibitors(Coagulation factor XII inhibitors), KLKB1 inhibitors(Plasma kallikrein inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Acute Ischemic Stroke

Inactive Indication-

Originator Organization

Yunnan Zhongke Longjin Biotechnology Co., Ltd.

Active Organization

Yunnan Zhongke Longjin Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价注射用 ZKLJ02 在中国健康研究参与者中单次静脉给药的安全性和耐受性。次要目的： (1) 评价注射用 ZKLJ02 在中国健康研究参与者中单次静脉给药的药代动力学（PK）特征； (2) 评价注射用 ZKLJ02 在中国健康研究参与者中单次静脉给药的药效动力学（PD）特征； (3) 评价注射用 ZKLJ02 在中国健康研究参与者中单次静脉给药的免疫原性。 (4) 初步探索 PK/PD 相关性。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single intravenous administration of ZKLJ02 for injection in Chinese health research participants. Secondary objectives: (1) To evaluate the pharmacokinetic (PK) characteristics of a single intravenous administration of ZKLJ02 for injection in Chinese health research participants; (2) To evaluate the pharmacodynamic (PD) characteristics of a single intravenous administration of ZKLJ02 for injection in Chinese health research participants; (3) To evaluate the immunogenicity of a single intravenous administration of ZKLJ02 for injection in Chinese health research participants. (4) To preliminarily explore the PK/PD correlation.

Start Date11 Aug 2025

Sponsor / Collaborator

Yunnan Zhongke Longjin Biotechnology Co., Ltd.

100 Clinical Results associated with ZKLJ02

Login to view more data

100 Translational Medicine associated with ZKLJ02

Login to view more data

100 Patents (Medical) associated with ZKLJ02

Login to view more data

100 Deals associated with ZKLJ02

Login to view more data